Alzheimer-kór: vizsgálatok itt: Horvátország
9 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
- Where
- Grad Zagreb, Rijeka, Split, Varazdin, Zagreb
- Életkor
- 55 év to 90 év
- People
- 426 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07011732 · EU 2025-520613-31-00 - 2. fázisTaking peopleA Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
- Where
- Zagreb
- Életkor
- 55 év and over
- People
- 370 worldwide
- Run by
- Intra-Cellular Therapies, Inc.
See details and how to joinNCT06540833 - 2. fázisTaking peopleA Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
- Where
- Grad Zagreb, Zagreb
- Életkor
- 55 év and over
- People
- 320 worldwide
- Run by
- Intra-Cellular Therapies, Inc.
See details and how to joinNCT06651567 · EU 2024-514680-26-00 - 3. fázisTaking peopleA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Where
- Grad Zagreb, Zagreb
- Életkor
- 55 év to 90 év
- People
- 406 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
- Where
- Grad Zagreb, Osijek, Rijeka
- Életkor
- 60 év to 85 év
- People
- 586 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06976216 · EU 2025-520746-30-00 - 3. fázisTaking peopleOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
- Where
- Grad Zagreb
- Életkor
- 55 év to 90 év
- People
- 1000 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00 - 3. fázisTaking peopleA Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- Where
- Grad Zagreb, Rijeka, Split, Varazdin, Zagreb
- Életkor
- 55 év to 90 év
- People
- 650 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00 - 2. fázisTaking peopleA study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease
- Where
- Grad Zagreb
- Életkor
- 18 év and over
- People
- 216 worldwide
- Run by
- Intra-Cellular Therapies Inc.
See details and how to join2024-513035-25-00 · EU 2024-513035-25-00 - 3. fázisTaking peopleA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
- Where
- Zagreb
- Életkor
- 55 év to 90 év
- People
- 410 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05511363